The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs)

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Pantaleo, Maria A ^a,b   Astolfi, Annalisa ^a,b   Nannini, Margherita ^a   Biasco, Guido ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C RECEPTOR;

ARTICLE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; MUTATIONAL ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; RECEPTOR, IGF TYPE 1;

EID: 78149421527     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-117     Document Type: Article

References (59)

1. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-18. 10.1038/nrc1387, 15229476.
2. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of diseases: signalling of the insulin-like Growth Factor 1 Receptor pathway-therapeutic perspectives in cancer. Nature Clin Pract Oncology 2007, 4:591-602.
3. Ryan PD, Goss PE. The emerging role of insulin-like growth factor pathway as therapeutic target in cancer. The Oncologist 2008, 13:16-24. 10.1634/theoncologist.2007-0199, 18245009.
4. Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D. The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 2010, 29:251-62. 10.1038/onc.2009.316, 2843625, 19838209.
5. Kappel CC, Velez-Yanguas MC, Hirschfeld S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994, 54:2803-7.
6. Savage SA, Woodson K, Walk E, Modi W, Liao J, Douglass C, Hoover RN, Chanock SJ, . National Osteosarcoma Etiology Study Group Analysis of genes critical for growth regulation identifies Insulin-like Growth Factor 2 Receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev 2007, 168:1667-74. National Osteosarcoma Etiology Study Group.
7. Scotlandi K, Benini S, Sarti M, Serra M, Lollini P-L, Maurici D, Picci P, Triche TJ, Baldini N. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996, 56:4570-4.
8. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman L. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997, 272:30822-7. 10.1074/jbc.272.49.30822, 9388225.
9. Friedrichs N, Küchler J, Endl E, Koch A, Czerwitzki J, Wurst P, Metzger D, Schulte JH, Holst MI, Heukamp LC, Larsson O, Tanaka S, Kawai A, Wardelmann E, Buettner R, Pietsch T, Hartmann W. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 2008, 216:428-39. 10.1002/path.2438, 18855347.
10. Van der Ven LT, Roholl PJ, Gloudemans T, Van Buul-Offers SC, Welters MJ, Bladergroen BA, Faber JA, Sussenbach JS, Den Otter W. Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues. Br J Cancer 1997, 75:1631-40. 2223537, 9184179.
11. Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998, 69:21-27. 10.1002/(SICI)1096-9098(199809)69:1<21::AID-JSO5>3.0.CO;2-M, 9762887.
12. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 1999, 59:3588-3591.
13. de Alava E, Panizo A, Antonescu CR, Huvos AG, Pardo-Mindán FJ, Barr FG, Ladanyi M. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000, 156:849-855. 1876855, 10702401.
14. Scotlandi K, Avnet S, Benini S, Manara MC, Serra M, Cerisano V, Perdichizzi S, Lollini PL, De Giovanni C, Landuzzi L, Picci P. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 2002, 101:11-16. 10.1002/ijc.10537, 12209582.
15. Busund LT, Ow KT, Russell P, Crowe PJ, Yang JL. Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Arch 2004, 444:142-148. 10.1007/s00428-003-0931-y, 14673647.
16. Ahlen J, Wejde J, Brosjo O, von Rosen A, Weng WH, Girnita L, Larsson O, Larsson C. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 2005, 11:206-216.
17. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990, 1:325-31.
18. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994, 94:445-8. 10.1172/JCI117344, 296329, 8040287.
19. Shapiro DN, Jones BG, Shapiro LH, Dias P, Houghton PJ. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 1994, 94:1235-42. 10.1172/JCI117441, 295208, 8083365.
20. Liu X, Turbyville T, Fritz A, Whitesell L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 1998, 58:5432-8.
21. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005, 65:11118-28. 10.1158/0008-5472.CAN-04-3841, 16322262.
22. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009, 9:748-60. 10.2174/156800909789271495, 19754359.
23. Zha J, Lackner MR. Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy. Clin Cancer Res 2010, 16:2512-7. 10.1158/1078-0432.CCR-09-2232, 20388853.
24. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opinion Oncology 2008, 20:419-427.
25. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, Croci S, Perdichizzi S, Zambelli D, Serra M, García-Echeverría C, Hofmann F, Picci P. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005, 65:3868-76. 10.1158/0008-5472.CAN-04-3192, 15867386.
26. Toretsky JA, Gorlick R. IGF-1R targeted treatment of sarcoma. Lancet Oncol 2010, 11:105-106. 10.1016/S1470-2045(09)70391-2, 20036195.
27. Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, Serra M, Manara MC, Picci P, Baldini N. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998, 58:4127-4131.
28. Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, García-Echeverría C, Picci P, Scotlandi K. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007, 13:1322-1330. 10.1158/1078-0432.CCR-06-1518, 17317844.
29. Benini S, Manara MC, Baldini N, Cerisano V, Massimo S, Mercuri M, Lollini PL, Nanni P, Picci P, Scotlandi K. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001, 7:1790-7.
30. Martins AS, Mackintosh C, Martín DH, Campos M, Hernández T, Ordóñez JL, de Alava E. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006, 12:3532-40. 10.1158/1078-0432.CCR-05-1778, 16740780.
31. Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, Feng L, Behrens C, Prudkin L, Miller YE, Lee JJ, Lippman SM, Hong WK, Wistuba II, Lee HY. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res 2009, 69:7439-48. 10.1158/0008-5472.CAN-08-3792, 2745504, 19738076.
32. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008, 26:4078-85. 10.1200/JCO.2007.13.4429, 2654368, 18757322.
33. Donovan EA, Kummar S. Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol 2008, 66:91-8. 10.1016/j.critrevonc.2007.09.003, 2374741, 17977741.
34. Gong Y, Yao E, Shen R, Goel A, Arcila M, Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, Ladanyi M, Pao W. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507) [abstract]. PLoS One 2009, 4:e7273. 10.1371/journal.pone.0007273, 2752171, 19806209.
35. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009, 27:2516-2522. 10.1200/JCO.2008.19.9331, 19380445.
36. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008, 105:8387-8392. 10.1073/pnas.0803383105, 2448846, 18550829.
37. Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, Maki RG, DeMatteo RP, Besmer P, Antonescu CR. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008, 14:3204-3215. 10.1158/1078-0432.CCR-07-1984, 18483389.
38. Pantaleo MA, Astolfi A, Di Battista M, Di Battista M, Heinrich MC, Paterini P, Scotlandi K, Santini D, Catena F, Manara MC, Nannini M, Maleddu A, Saponara M, Lolli C, Formica S, Biasco G. Insulin-like growth factor 1 receptor (IGF1r) expression in wild-type GIST: a potential novel therapeutic target. Int J Cancer 2009, 125:2991-2994. 10.1002/ijc.24595, 19672856.
39. Janeway KA, Zhu MJ, Barretina J, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer 2010, 127:2718-22. 10.1002/ijc.25247, 20162573.
40. Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, Belvederesi L, Cascinu S, Valeri N, Cellerino R. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 2008, 19:1293-8. 10.1093/annonc/mdn040, 18372285.
41. Hirota S, Isozaki K, Moriyama Y, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain of function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580. 10.1126/science.279.5350.577, 9438854.
42. Demetri GD, von Mehren M, Blanke CD, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480. 10.1056/NEJMoa020461, 12181401.
43. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-38. 10.1016/S0140-6736(06)69446-4, 17046465.
44. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 2003, 21:4342-9. 10.1200/JCO.2003.04.190, 14645423.
45. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD. Primary and Secondary Kinase Genotypes Correlate with the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor. J Clin Oncol 2008, 33:5352-5359.
46. Dei T, Ellis I. Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?. Eur J Cancer 2005, 41:1383-92. 10.1016/j.ejca.2005.03.018, 15919198.
47. Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: lessons from real trials. Clin Trial 2010, 29:1077-83.
48. Belinsky MG, Skorobogatko YV, Rink L, Pei J, Cai KQ, Vanderveer LA, Riddell D, Merkel E, Tarn C, Eisenberg BL, von Mehren M, Testa JR, Godwin AK. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer 2009, 48:886-96. 10.1002/gcc.20689, 2830286, 19585585.
49. Astolfi A, Nannini M, Pantaleo MA, Di Battista M, Heinrich MC, Santini D, Catena F, Corless CL, Maleddu A, Saponara M, Lolli C, Di Scioscio V, Formica S, Biasco G. A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Lab Invest 2010, 90:1285-94. 10.1038/labinvest.2010.110, 20548289.
50. García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004, 5:231-9. 10.1016/S1535-6108(04)00051-0, 15050915.
51. Romano G, Prisco M, Zanocco-Marani T, Peruzzi F, Valentinis B, Baserga R. Dissociation between resistance to apoptosis and the transformed phenotype in IGF-I receptor signaling. J Cell Biochem 1999, 72:294-310. 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0, 10022512.
52. Pantaleo MA, Landuzzi L, Nicoletti G, Nanni C, Boschi S, Piazzi G, Santini D, Di Battista M, Castellucci P, Lodi F, Fanti S, Lollini PL, Biasco G. Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. Clin Exp Med 2009, 9:199-205. 10.1007/s10238-009-0033-5, 2709232, 19225718.
53. Lorincz A, Redelman D, Horváth VJ, Bardsley MR, Chen H, Ordög T. Progenitors of interstitial cells of cajal in the postnatal murine stomach. Gastroenterology 2008, 134:1083-93. 10.1053/j.gastro.2008.01.036, 2435491, 18395089.
54. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007, 13:671-86. 10.2174/138161207780249173, 17346183.
55. Pantaleo MA, Nannini M, Di Battista M, Catena F, Biasco G. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. Cancer Treat Rev 2010, 36:63-8. 10.1016/j.ctrv.2009.10.004, 19914780.
56. Rikhof B, van Doorn J, Suurmeijer AJ, Rautenberg MW, Groenen PJ, Verdijk MA, Jager PL, de Jong S, Gietema JA, van der Graaf WT. Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol 2009, 20:1582-8. 10.1093/annonc/mdp038, 19276395.
57. Guiteau J, Fanucchi M, Folpe A, Staley CA, Kooby DA. Hypoglycemia in the setting of advanced gastrointestinal stromal tumor. Am Surg 2006, 72:1225-30.
58. Escobar GA, Robinson WA, Nydam TL, Heiple DC, Weiss GJ, Buckley L, Gonzalez R, McCarter MD. Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer 2007, 7:13. 10.1186/1471-2407-7-13, 1781460, 17229322.
59. Hall KF, Lin CL, Wang TH, Chang RH, Chen HM. A case of gastrointestinal stromal tumor with hyperinsulinemic hypoglycaemia. Chang Gung Med J 2008, 31:107-11.